Skip to main content
. 2018 Mar 6;23(6):658–e72. doi: 10.1634/theoncologist.2017-0325

Table 3. Subject disposition during dose expansion (stage 2).

image

a

Subjects who completed cycle 2 day 1 assessments were defined as completers.

b

Subjects who received any IMP were included in safety analysis.

c

Subjects who received at least one cycle of IMP were analyzed for efficacy.

Abbreviations: C2 D1, cycle 2 day 1; IMP, investigational medicinal product; NSCLC, non‐small cell lung cancer.